New distribution! Reach relevant USA TODAY Network news sites. Get started ›

New distribution! Reach relevant USA TODAY Network news sites. Get started ›

World Media Directory · RSS · Email Newsletters

There were 1,013 press releases posted in the last 24 hours and 476,153 in the last 365 days.

Press Releases on June 28, 2024

1,517 Press Releases

Published on June 28, 2024 - 12:54 GMT

Human medicines European public assessment report (EPAR): Balversa, Erdafitinib, Status: Opinion

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Balversa, intended for the treatment of urothelial carcinoma harbouring …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:54 GMT

Human medicines European public assessment report (EPAR): Enzalutamide Viatris, enzalutamide, Status: Opinion

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Enzalutamide Viatris, intended for the treatment of prostate cancer. The …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:54 GMT

Human medicines European public assessment report (EPAR): Eurneffy, epinephrine, Status: Opinion

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Eurneffy, intended for emergency treatment of allergic reactions ( …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Human medicines European public assessment report (EPAR): Mresvia, Single-stranded 5' capped mRNA encoding the Respiratory ...

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product mResvia, intended for the prevention of lower respiratory tract (LRT) …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Human medicines European public assessment report (EPAR): Nilotinib Accord, nilotinib, Status: Opinion

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Nilotinib Accord, intended for the treatment of chronic myelogenous …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Global Procurement-as-a-Service (PaaS) Market Report 2024: Trends, Strategies, And Opportunities

The Business Research Company’s Procurement-As-A-Service Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033 LONDON, GREATER LONDON, UK, June 28, 2024 /⁨EINPresswire.com⁩/ -- The procurement-as-a-service (PaaS) model involves …

Distribution channels: Business & Economy, Consumer Goods ...
Published on June 28, 2024 - 12:53 GMT

Human medicines European public assessment report (EPAR): Ordspono, Odronextamab, Status: Opinion

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional1marketing authorisation for the medicinal product Ordspono2, intended for the treatment of follicular lymphoma …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Human medicines European public assessment report (EPAR): Piasky, Crovalimab, Status: Opinion

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Piasky, intended as monotherapy for the treatment of adult and …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Human medicines European public assessment report (EPAR): Winrevair, Sotatercept, Status: Opinion

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Winrevair2, intended for the treatment of pulmonary arterial …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Summary of opinion: Pegasys, 27/06/2024 Positive

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Pegasys. The marketing authorisation holder for this medicinal …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Human medicines European public assessment report (EPAR): Dabigatran etexilate Teva , dabigatran etexilate, Status: Withdrawn ...

Based on the review of the data and the company's response the Agency's questions, at the time of the withdrawal, concerns remained on the presence of nitrosamine impurities in the medicine and its provisional opinion was that Dabigatran etexilate …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Summary of opinion: Infanrix Hexa, 27/06/2024 Positive

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Infanrix hexa. The marketing authorisation holder for this …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Summary of opinion: Xalkori, 27/06/2024 Positive

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Xalkori. The marketing authorisation holder for this medicinal …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Positive CHMP opinion on first-in-class medicine to treat pulmonary arterial hypertension

EMA has recommended granting a marketing authorisation in the European Union (EU) for Winrevair (sotatercept) to treat adult patients with pulmonary arterial hypertension (PAH), in combination with other specific PAH therapies, to improve exercise capacity …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

EMA recommends revoking conditional marketing authorisation for Ocaliva

EMA’s human medicines committee (CHMP) has concluded its review of the medicine Ocaliva (obeticholic acid) and has recommended that the medicine’s marketing authorisation be revoked, because its benefits are no longer considered to outweigh its risks. …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

First nasal adrenaline spray for emergency treatment against allergic reactions

EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Eurneffy (epinephrine), the first medicine to be taken through the nose for the emergency treatment of allergic reactions (anaphylaxis). …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Summary of opinion: Imcivree, 27/06/2024 Positive

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Imcivree. The marketing authorisation holder for this …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Summary of opinion: Betmiga, 27/06/2024 Positive

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Betmiga. The marketing authorisation holder for this medicinal …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Summary of opinion: Beyfortus, 30/05/2024 Positive

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Beyfortus. The marketing authorisation holder for this …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 28, 2024 - 12:53 GMT

Summary of opinion: Tepkinly, 27/06/2024 Positive

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tepkinly. The marketing authorisation holder for this …

Distribution channels: Healthcare & Pharmaceuticals Industry

Previous 40 41 42 43 44 45 46 47 48 49 50 Next

Previous Day 2024 Calendar Next Day